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Control of Seasonal and Pandemic Influenza
Seasonal influenza is an acute respiratory illness caused by influ-
enza virus. This disease has a strong impact on public health 
worldwide causing, annually, 3 to 5 million cases of severe ill-
ness and between 250,000 and 500,000 deaths, mainly among 
children, elderly and immune-suppressed individuals (http://
www.who.int/mediacentre/factsheets/fs211/en/). The best way 
to fight the impact of this disease is to vaccinate the population. 
Available vaccines are mostly inactivated ones, with a smaller 
proportion of live attenuated vaccines. Inactivated vaccines are 
produced mainly in embryonated chicken eggs and to a lesser 
extent in cell culture.1,2 Influenza vaccines induce protection in 
immunized individuals through the generation of neutralizing 
antibodies, mainly directed against the viral envelope glycopro-
tein hemagglutinin (HA). Virus antigenic variants arise con-
stantly due to the high variability of the gene encoding the HA. 
Given the high rate of antigenic variation of the HA, antibod-
ies that neutralize a subtype are often ineffective to neutralize 
other subtypes, and consequently the strains included in seasonal 
vaccines must be constantly updated. Vaccine efficiency severely 
diminishes when new strains emerge with antigenic changes in 
the virus envelope proteins, and situations where the antigenic 
matching between vaccine strains and the new circulating ones 
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in pursuit of better influenza vaccines, many strategies are 
being studied worldwide. An attractive alternative is the 
generation of a broadly cross-reactive vaccine based on the 
induction of cytotoxic T-lymphocytes (CTL) directed against 
conserved internal antigens of influenza A virus. The feasibility 
of this approach using recombinant viral vectors has recently 
been demonstrated in mice and humans by several research 
groups. However, similar results might also be achieved 
through immunization with viral proteins expressed in a 
prokaryotic system formulated with the appropriate adjuvants 
and delivery systems. This approach would be much simpler 
and less expensive. Recent results from several laboratories 
seem to confirm this is as a valid option to be considered.
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is sub-optimal are not exceptional. On rare occasions, com-
pletely new pandemic influenza variants arise, to which most of 
the human population has not been exposed. Under these cir-
cumstances, population immunity is low or null, allowing for an 
accelerated transmission of the new strain worldwide, which can 
have devastating consequences in terms of human lives. A recent 
analysis of the effectiveness of influenza vaccines holds that the 
immunity generated during certain seasons is at best moderate, 
when not significantly low or absent. In the ideal situation when 
antigenic matching between vaccines and circulating strains is 
optimal, average effectiveness was 69%.3 During an outbreak of 
a pandemic strain there is a risk that the development of a vaccine 
for the emerging strain be too slow and, when available, come 
too late.
Improving the Performance of Current Vaccines
Much effort has been devoted to the improvement of current 
vaccines using different strategies, such as exploring new routes 
of vaccine administration, like oral,4 intranasal,5 or intradermal 
immunization,6 new delivery systems like micro-needles7 or 
addition of adjuvants which might allow for an increase in the 
humoral and cellular responses,8,9 and a significant decrease in 
the dose of protective antigen needed.10 It has also been reported 
that variations in the method of inactivation can significantly 
improve vaccine efficacy.11,12
Development of New Generation Vaccines
The main line of work in this field is focused on generating totally 
new vaccines using genetic engineering techniques. Conspicuous 
examples of this are: expression of the viral HA by means of 
recombinant vectors,13-15 production of virus-like particles (VLP) 
of influenza containing the influenza proteins HA and Matrix1 
(M1),16 production of recombinant HA subunit vaccines in insect 
cells through the baculovirus system,17 and production of recom-
binant HA or its fusion with flagellin in Escherichia coli.18,19 DNA 
vaccines and peptide based vaccines have already been assayed in 
humans with promising results.20,21 While many of these strate-
gies proved to be very efficient and in some cases induced signifi-
cant increases in cross-reactive immune responses, they did not 
completely solve the problems derived from the high antigenic 
variability of influenza virus.
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their functional role during the viral replication cycle. It is well 
known that while they cannot induce neutralizing antibodies 
in infected or immunized animals, they are capable of induc-
ing strong cellular immunity. For many years it has been known 
that mice recovering from infection with a certain subtype of 
influenza A virus have some protection against lethal challenge 
with a heterologous strain, and that the immunological basis of 
this phenomenon is mediated mainly by anti-influenza specific 
CTLs.33,34 These CTLs recognize highly conserved amino acid 
sequences of certain viral proteins, mainly proteins within the 
virus particle, exposed by the MHC class I pathway on the sur-
face of infected cell.35-38 Although it has not been clearly estab-
lished yet, there is some evidence of correlation between CTLs 
and protection, in humans.39,40
The cross-reactivity of polyclonal virus-specific CD8+ T-cell 
populations (obtained from european subjects), which target 
cells pulsed with H5N1-derived peptides or NP gene-transfected 
cells of the same avian influenza virus, demonstrates that human 
CTL response displays a high degree of cross-reactivity for very 
diverse influenza virus subtypes.41
The concept that a vaccine formulated with a recombinant 
antigen unable to induce neutralizing antibodies can protect 
immunized mice from a lethal viral challenge was validated in 
the early 90s. Earlier experiences with a NP-based T-cell vaccine 
using purified recombinant NP (rNP) as a vaccine antigen indi-
cated the validity of this concept,42 which was further confirmed 
with a genetic vaccine containing a NP gene-carrying plasmid, 
which was able to protect mice against lethal challenges with an 
heterologous influenza virus.43
Recombinant Vector Based T-cell Vaccine  
for Influenza
Very recently, the use of recombinant adenovirus vectors express-
ing viral proteins NP and M2 (full length or M2e), showed that 
a T-cell vaccine against influenza could be extremely effective in 
mice.44,45 Furthermore, in a similar approach in a Phase I clinical 
trial, a modified Vaccinia virus Ankara (MVA) vector, encoding 
NP and M1, generated potent T-cell CD8+ specific immunity 
in immunized humans.46 A Phase II clinical trial, conducted in 
healthy volunteers showed the efficacy of this vaccine to protect 
against flu symptoms after a challenge with live virus.47
Development of a T-cell Vaccine Based  
on Adjuvanted rNP Produced in a Prokaryotic System
Although influenza vaccine candidates based on recombinant 
vectors are very promising, it should be noted that safety trials 
for this strategy will take a long time before they are approved 
and massively available in the market. Furthermore, its produc-
tion involves the handling of sophisticated and expensive tech-
nology not available in many developing countries. Therefore, it 
would be important to develop vaccines able to produce the same 
results but using simpler and less expensive production systems. 
Recently published results suggest that a NP based T-cell vaccine 
against influenza A could also be achieved using the recombinant 
A Universal Vaccine for Influenza
This line of work is pursuing a “universal” type of vaccine, that 
is, a vaccine that can protect against almost all known subtypes 
of influenza, including pandemic strains.22 In this regard three 
main strategies are being pursued:
Induction of neutralizing antibodies against highly conserved 
regions of the HA. The dogma that the influenza virus neutraliza-
tion is mediated only by antibodies that bind to the globular head 
of the HA protein has been recently challenged. Several laborato-
ries worldwide have generated broad spectrum human monoclo-
nal antibodies capable of neutralizing the virus by binding to a 
highly conserved region of the HA (the stem or stalk domain).23 
Some of these monoclonal antibodies are capable of reacting with 
all the known specificities of HA, and it has been demonstrated 
that passive transfer of this kind of antibodies to mice and fer-
rets may protect against a challenge with heterologous strains.24 
However, it is difficult to find the appropriate antigen capable of 
efficiently inducing such antibodies in vivo after immunization.25
An influenza A vaccine based on the ectodomain of the 
Matrix2 protein. The M2 protein (encoded in the same gene 
as the M1 protein) is a tetramer, functioning as an ion channel, 
and is present in very low amounts on the viral particle surface. 
The N-terminus of this protein (known as ectodomain or M2e) 
is highly conserved among strains of almost any origin. Based on 
this, M2e has been postulated as a very good candidate for the 
development of a universal vaccine. This assumption has been 
thoroughly demonstrated in pre-clinical models using various 
strategies.26,27 It was demonstrated that alveolar macrophages 
and Fc-receptors are fundamental for anti-M2e IgGs-mediated 
protection to occur.28 Currently, the potential of an M2e-based 
universal vaccine is also being analyzed in human clinical tri-
als.29,30 Although a vaccine based on the induction of anti-M2e 
antibodies is very promising, it will probably need to be com-
bined with other conserved influenza antigens, able to elicit an 
adequate cellular response for a fully protective immunity.
A T-cell vaccine for influenza. The goal of a T-cell vaccine is 
to induce a strong response of specific CD4 + and CD8 + lympho-
cytes which may contribute to pathogen clearance by recognition 
and elimination of infected cells. For several important human 
infectious diseases, the efficacy of T-cells to induce therapeutic 
or prophylactic vaccines based on the use of replication-deficient 
viral vectors has already been established.31 In the particular case 
of influenza, the generation of a non-sterilizing cellular based 
immunity is being sought; an immunity which would substan-
tially decrease morbidity and mortality induced by the infection. 
Cytotoxic T- lymphocytes (CTL) are very effective in killing tar-
get cells by different mechanisms, thus eliminating the viruses 
from the infected organisms. In the case of influenza, it has been 
demonstrated that this type of immunity can protect mice from 
a lethal challenge with influenza A virus.32
Candidate Proteins for a T-cell Vaccine for Influenza
Unlike surface glycoproteins, proteins located within the influ-
enza virion such as the NP and M1 are highly conserved due to 
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It has also been effective in decreasing the minimum antigen 
dose required to obtain protection after pulmonary delivery of 
an influenza vaccine.59 In mice, it was shown that IMX greatly 
improves the efficiency of a commercial vaccine increasing 
hetero-subtypic protection and CTL response.60 In humans, a 
trivalent inactivated influenza vaccine formulated with IMX, 
elicited a sharp increase in the CTL response compared with 
those individuals that received the unadjuvanted vaccine.61,62 
Rimmelzwaan et al.62 found that IMX significantly increases 
the anti-HA CTL response, but not an anti-NP CTL response. 
This is different from what happens in vivo, where after infec-
tion with influenza virus, the anti NP CTL response is domi-
nant. In our experience, analysis of the values of IgG subtypes 
and interleukins in the sera of mice that had been immunized 
with IMX-formulated rNP clearly indicated that the response 
obtained had a strong Th1 profile.63 These experiments also 
showed the generation of high titers of IgG anti-NP. This should 
be also taken into account, since it has been demonstrated that 
specific high titers obtained after immunization of mice with 
rNP contributed to a rapid antibody-dependent elimination of 
the year 2009 H1N1 pandemic virus strain and that high anti 
NP titers correlated with an increase in the CD8+ response.64,65 
These results strongly suggest that antibodies induced by immu-
nization with rNP-IMX could also contribute, significantly, to a 
T-cell vaccine.
Are Adjuvanted Split Virus Vaccines Able to Induce  
a T Cell Response?
As mentioned previously, Rimmelzwaan et al.62 found that, con-
trary to what happens in infected individuals, the formulation 
of a split trivalent inactivated vaccine with IMX promotes the 
generation of CTL specific to HA but not NP. Lamere et al.64 
found that the lack of immunological reactivity of the endog-
enous NP contained in the split trivalent inactivated vaccine in 
mice, may be slightly improved by adding lipopolysaccharides to 
the vaccine formulation. In humans, preceding titers of specific 
anti NP IgG can be boosted in only few cases in subjects immu-
nized with conventional trivalent vaccines. In a similar way, 
Savard et al.66 found that NP and M1 proteins present in split 
virion seasonal flu vaccine, are not immunogenic in immunized 
mice. However they showed that immunization of mice and fer-
rets with the same vaccine adjuvanted with papaya mosaic virus 
nanoparticles triggered a cell-mediated immune response to NP 
and M1, and long-lasting protection in animals challenged with 
a heterosubtypic influenza strain. Based on the above mentioned 
facts, there is some evidence that the endogenous NP contained 
in split influenza vaccines can be stimulated to produce a CTL 
response. However, the current processes of vaccine manufactur-
ing are not validated to assess the content of NP in each batch, 
nor is it certain that the NP complexed with the genomic RNA 
in whole inactivated virus will be the most suitable antigen. On 
this basis it is tempting to hypothesize that for the purpose of 
generating an influenza specific CTL response, it would be more 
convenient to use recombinant NP, combined with a seasonal 
subunit vaccine.
protein produced in E. coli, which would be a far more simple 
and inexpensive system. In our laboratory, we have confirmed 
other group’s results, that is that the NP protein can be easily 
produced and purified in large quantities at low cost in E. coli
.
48-50 
The same appears true for other influenza proteins which are also 
candidates for a T-cell vaccine, such as M1 and M2.50,51
The main limitation of this approach is the difficulty to 
induce a strong CTL response in animals immunized with an 
exogenous protein.31 However, exogenous proteins may induce 
a CTLs response by the phenomenon known as cross presenta-
tion,52 and it is known that cross-presentation of an exogenous 
protein can be greatly stimulated with certain adjuvants which 
favor this process.53 Recently, several reports confirmed the effec-
tiveness of vaccines formulated with adjuvanted rNP to protect 
vaccinated animals against a lethal challenge of homologous or 
heterologous virus. Intranasal administration of cholera toxin 
combined with rNP protected against multiple viral subtypes.49 
The combination of recombinant NP and M2 formulated as 
liposomes stimulated a marked increase of specific CTLs and 
protected the vaccinated mice from a lethal challenge with the 
H5N1 avian strain.50 A vaccine formulated with rNP and a TLR3 
ligand, induced specific CTLs and protection against lethal chal-
lenge from influenza virus.54 Fortunately, the knowledge on the 
possibilities of increasing the CTL responses to a recombinant 
protein is constantly increasing. A priori, there are multiple 
potential formulations that could lead to the optimization of a 
T-cell based rNP vaccine for influenza. In the pursuit of such a 
strategy, our laboratory has recently begun a systematic search 
of adjuvants able to promote a strong CTL response in animals 
vaccinated with rNP.
Iscomatrix Adjuvanted Influenza Vaccines
Iscomatrix (IMX) adjuvant is an immunostimulating system 
which also optimizes the process of antigen delivery, and is very 
efficient in obtaining a strong CTL response after immuniza-
tion with exogenous protein.55,56 IMX consists of nanoparticles 
of about 40–50 nm in diameter with a strong negative charge, 
generated by the self assembly of phospholipids, cholesterol and 
saponins.55 The negative charge of these particles favors their 
interaction with basic proteins such as the NP.57 After immuni-
zation, the nanoparticles containing the antigen migrate to the 
draining lymph nodes, where they are captured and internal-
ized by lymphoid resident dendritic cells (DC). IMX favors the 
process of extracellular antigen translocation from the endosome 
to the cytosol for proteasomal degradation. The processed pep-
tides can then enter the major histocompatibility complex class 
I (MHC I) pathway, favoring the mechanism of cross presenta-
tion and the generation of CD8+ lymphocytes. The DCs that 
have taken up the particles are also activated, releasing many 
cytokines and lymphokines which stimulate the magnitude of 
the immune response. On the other hand, this system also has a 
strong stimulating activity on the humoral arm of the immune 
response.56 This system has been successful when combined 
with inactivated influenza vaccines. It has proven very effec-
tive in stimulating mucosal immunity by the intranasal route.58 
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laboratory we are currently developing delivery systems which 
include rNP in adjuvant loaded nanoparticles. In our work we 
have used rNP alone, however it is clear that the inclusion of 
other proteins with similar properties such as M1 and M2 is 
desirable. The production of vaccines based on this technology 
would be inexpensive due to their simplicity, and the technol-
ogy could be certainly implemented in developing countries, 
which are now almost completely dependent on external sources 
of production. A vaccine of this type should be combined with 
the seasonal vaccine to elicit both robust influenza-specific anti-
body and CTL responses for maximal protection.
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Conclusions
In recent years the trend in the field of recombinant vaccines 
development has been the use of viral vectors when looking for a 
strong cellular response31 and purified proteins when looking for 
a humoral response.67 The use of purified recombinant proteins 
for the development of vaccines against infectious agents that 
require a strong cellular response has been virtually neglected. 
However, our results and those of other laboratories confirm 
that it is possible to induce cell-mediated immune responses 
with purified proteins formulated with the appropriate adju-
vants. Such formulations may even be improved by using par-
ticulate delivery systems. This type of methodology has been 
developed extensively in recent years and has also proved to be a 
very powerful method of inducing cellular immunity.68-70 In our 
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